Arquitos Capital Management Q4 2024 Commentary

2025-02-05 07:10:00 ET

Summary

• Arquitos Fund achieved a 29.6% return in 2024, outperforming the S&P 500's 25.0% return, driven by strategic investments in key positions.
• Finch Therapeutics, a 7% portfolio holding, won a significant patent case, potentially leading to enhanced damages and substantial share price appreciation.
• Liquidia Therapeutics is poised for a strong 2025 with FDA approval expected for Yutrepia, which could dominate the PAH and PH-ILD markets.
• Nam Tai Property and ENDI Corp remain strong holdings, with Nam Tai resolving key issues and ENDI providing stable, high-potential returns.

Dear Partner

Arquitos returned 29.6% net of fees and expenses in 2024, compared to 25.0% for the S&P 500 ( SP500 , SPX ).

I am as confident as I have ever been in the potential for our top four positions to perform exceptionally well in 2025. Please find my commentary on each of them below....

Read the full article on Seeking Alpha

For further details see: